Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.
about
Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenesAntimicrobial drug prescribing for pneumonia in ambulatory careEmerging mechanisms of fluoroquinolone resistanceBTS Guidelines for the Management of Community Acquired Pneumonia in AdultsActivity of telithromycin and comparators against bacterial pathogens isolated from 1,336 patients with clinically diagnosed acute sinusitisSub-inhibitory concentrations of vancomycin prevent quinolone-resistance in a penicillin-resistant isolate of Streptococcus pneumoniaeBench-to-bedside review: Therapeutic options and issues in the management of ventilator-associated bacterial pneumoniaGuidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and preventionFluoroquinolone resistance among Streptococcus pneumoniae in Hong Kong linked to the Spanish 23F cloneAntibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trialMaintaining fluoroquinolone class efficacy: review of influencing factors.In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.Gatifloxacin: a new fluoroquinolone.Gatifloxacin, an advanced 8-methoxy fluoroquinolone.Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data.Ofloxacin-like antibiotics inhibit pneumococcal cell wall-degrading virulence factors.Procalcitonin levels in acute exacerbation of COPD admitted in ICU: a prospective cohort study.Genome-wide dissection of globally emergent multi-drug resistant serotype 19A Streptococcus pneumoniae.Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains.Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.A comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research GroupFluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: identification of gyrA and parC and specification of point mutations associated with resistanceEfficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review.Risk factors associated with colonization by pneumococci with reduced susceptibility to fluoroquinolones in adult outpatients.Clonal dissemination of macrolide-resistant and penicillin-susceptible serotype 3 and penicillin-resistant Taiwan 19F-14 and 23F-15 Streptococcus pneumoniae isolates in Japan: a pilot surveillance studyHigh genetic diversity of ciprofloxacin-nonsusceptible isolates of Streptococcus pneumoniae in Poland.The next generation: fluoroquinolones in the management of acute lower respiratory infection in adultsPro/con debate: Should antimicrobial stewardship programs be adopted universally in the intensive care unit?Evaluation of the PASCO strep plus broth microdilution antimicrobial susceptibility panels for testing Streptococcus pneumoniae and other Streptococcal species.Rapid automated antimicrobial susceptibility testing of Streptococcus pneumoniae by use of the bioMerieux VITEK 2.Clonal groups of penicillin-nonsusceptible Streptococcus pneumoniae in Baltimore, Maryland: a population-based, molecular epidemiologic study.Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing.Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions.In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada.Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory seComparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci.Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci.Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States.
P2860
Q24600215-87C2C7C9-5804-41EF-8A68-531A3D80A767Q24620235-EAA76DF8-228E-4BA3-9103-27BCB9904DDAQ24644842-3C4F40BB-4402-4122-A008-52FE3D6EDEF4Q24675547-62D64202-3243-47BB-854F-C23FC1972D05Q24798440-9A461B97-9D97-40A4-9BF4-11B6B4482D0AQ24801022-D53AC8D6-7E77-4820-8C0E-FAE907155824Q24811492-DED06C05-886E-40FA-99B7-2C4BB38F7452Q28201389-97BFE1D8-E845-4019-8E2F-517E5F47837FQ28366621-F72B3B3D-115A-47E2-8264-486F1D617F87Q28476520-BE92056E-633C-4FD4-A4CC-2B5237729228Q30310427-B7B053A9-538E-4FA3-87A9-6837122F6DCFQ30612482-E68B7279-7593-4404-B108-9ACD5EA27B74Q31522155-D7A4DC50-AD30-410E-932B-2A67D890AE3CQ31975922-DDD57F9F-435B-4EC8-8871-FCE805BC1AD7Q33187513-CE10BF73-1A2C-437C-99C0-CE811757A67DQ33212929-43BEBCC6-076E-4D0F-BA6B-7C4ECEF97485Q33378956-A322F9F3-6908-4C58-B01A-032A9FCBCAA1Q33521377-0AFFF626-D307-4099-B168-07DF402542C0Q33549724-F7B80D57-D24D-41EA-A277-A3F0C05F075BQ33559055-203502CD-31CF-48E8-85F7-FFEF7486DBB5Q33593776-8F3A6246-9369-4429-92FB-967E3B15F038Q33593962-DBEF60FF-A939-497C-85F0-8AF66E23F571Q33594174-60FC6671-E9B6-4368-9962-F6E3A6145F78Q33595145-89D8ED75-4889-4AFD-8C55-207FC2EE4899Q33739099-2C117E07-C10E-4852-901A-BA4B5F1F529CQ33752905-46E0E97C-73ED-4EEB-96EC-FE0055A461A4Q33753151-9AF728E3-2823-4E4A-A569-7B71175C18E0Q33770218-39C90774-6B68-4F5C-BEE7-232D4B3BC794Q33801878-F99D1A45-6A9B-4FEF-850D-86BB4644D187Q33873338-3AF48DBB-1577-41A0-9B81-FD7C36D5B036Q33966759-9B135499-FF98-4DD5-8DDC-6ADF52E79036Q33968677-E21F2535-79F5-4E1E-9257-884F8CDBF3EDQ33970496-4701F6BC-410E-4F67-9248-B40D4E8E08C5Q33970955-415C5488-7187-46BD-A6DC-B7480573D92BQ33975560-B6F03FB0-2D17-4FA7-8226-A6781EDE9237Q33977709-02FDAB9D-2BC0-447A-A495-CBC49E310C65Q33978849-24E09007-039C-4368-8CFC-3D18F3B2F559Q33979988-9FEDD6F4-6F38-4EEF-8E90-A78A27ECC8EBQ33980313-F3C312B3-0C7E-45CF-B325-3C64F6C0C12DQ33980574-0A893756-6717-45C0-964E-76070DA9BF4C
P2860
Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Decreased susceptibility of St ...... acterial Surveillance Network.
@en
Decreased susceptibility of St ...... acterial Surveillance Network.
@nl
type
label
Decreased susceptibility of St ...... acterial Surveillance Network.
@en
Decreased susceptibility of St ...... acterial Surveillance Network.
@nl
prefLabel
Decreased susceptibility of St ...... acterial Surveillance Network.
@en
Decreased susceptibility of St ...... acterial Surveillance Network.
@nl
P2093
P1476
Decreased susceptibility of St ...... acterial Surveillance Network.
@en
P2093
P304
P356
10.1056/NEJM199907223410403
P407
P577
1999-07-01T00:00:00Z